Novartis invests in next generation therapies to reduce cardiovascular risk in patients with underlying lipid disorders - Seite 3

Disclaimer
The foregoing release contains forward-looking statements that can be identified by words such as "invests," "next generation," "option," "investigational," "expected," "pipeline," "commitment," "potential," "building," "portfolio," "will," "look forward," "options," or similar terms, or by express or implied discussions regarding potential marketing approvals for AKCEA-APO(a)-L_Rx, AKCEA-APOCIII-L_Rx and the other products in the Novartis cardiovascular portfolio, or regarding potential future revenues from AKCEA-APO(a)-L_Rx, AKCEA-APOCIII-L_Rx and the other products in the Novartis cardiovascular portfolio, or regarding the possible exercise of the options to license and commercialize AKCEA-APO(a)-L_Rx and AKCEA-APOCIII-L_Rx, or regarding the intended goals and objectives of the transaction with Ionis and Akcea and the license to commercialize AKCEA-APO(a)-L_Rx and AKCEA-APOCIII-L_Rx. You should not place undue reliance on these statements. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the necessary government approvals for the transaction or option exercises will be obtained in any particular time frame, or at all. Neither can there be any guarantee that any other closing conditions for the transaction or option exercises will be met in any particular time frame, or at all. Nor can there be any guarantee that the options to license and commercialize AKCEA-APO(a)-L_Rx and AKCEA-APOCIII-L_Rx will be exercised within the expected time frame, or at all. Neither can there be any guarantee that the transaction with Ionis and Akcea and license to commercialize AKCEA-APO(a)-L_Rx and AKCEA-APOCIII-L_Rx will achieve any of their intended goals and objectives, or in any particular time frame. Nor can there be any guarantee that AKCEA-APO(a)-L_Rx, AKCEA-APOCIII-L_Rx or the other products in the Novartis cardiovascular portfolio will be submitted or approved for sale in any market, or at any particular time. Neither can there be any guarantee that AKCEA-APO(a)-L_Rx, AKCEA-APOCIII-L_Rx or the other products in the Novartis cardiovascular portfolio will be commercially successful in the future. In particular, management's expectations regarding AKCEA-APO(a)-L_Rx, AKCEA-APOCIII-L_Rx and the other products in the Novartis cardiovascular portfolio, the transaction with Ionis and Akcea, and the options to license and commercialize AKCEA-APO(a)-L_Rx and AKCEA-APOCIII-L_Rx could be affected by, among other things, the potential that the intended goals and objectives of the transaction with Ionis and Akcea and the license to commercialize AKCEA-APO(a)-L_Rx and AKCEA-APOCIII-L_Rx may not be achieved or may take longer to achieve than expected; the uncertainties inherent in research and development, including unexpected clinical trial results and additional analysis of existing clinical data; unexpected regulatory actions or delays or government regulation generally, including an unexpected failure to obtain necessary government approvals for the transaction or option exercises, or unexpected delays in obtaining such approvals; the potential that any other closing conditions for the transaction or option exercises may not be met; the company's ability to obtain or maintain proprietary intellectual property protection; general economic and industry conditions; global trends toward health care cost containment, including ongoing pricing pressures; unexpected manufacturing issues, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.